Filter Results:
(1,381)
Show Results For
- All HBS Web
(1,381)
- People (6)
- News (260)
- Research (648)
- Events (11)
- Multimedia (33)
- Faculty Publications (501)
Show Results For
- All HBS Web
(1,381)
- People (6)
- News (260)
- Research (648)
- Events (11)
- Multimedia (33)
- Faculty Publications (501)
- October 2014 (Revised April 2023)
- Case
Gilead: Hepatitis C Access Strategy (A)
By: V. Kasturi Rangan, Vikram Rangan and David E. Bloom
Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the... View Details
Keywords: Healthcare; Pharmaceuticals; Pricing; Access To Care; Emerging Markets; Health Care and Treatment; Price; Strategy; Ethics; Health Industry; Pharmaceutical Industry
Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A)." Harvard Business School Case 515-025, October 2014. (Revised April 2023.)
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- 10 Nov 2016
- News
Bringing the Power of Platforms to Heath Care
- 23 Jul 2015
- News
How Pharma Can Offer More than Pills
- 26 May 2014
- News
Health Care Becomes Entrepreneurial (Finally)
- May 2021
- Supplement
Paul Levy: Confronting a 'Corporate Campaign' (B)
By: James K. Sebenius and Isaac Silberberg
Paul Levy, CEO of the Beth Israel Deaconess Medical Center hospital is faced with a formidable negotiation campaign to unionize staff at BIDMC. Armed only with his personal blog, does Paul stand a chance against the union's multi-million dollar organizing budget? View Details
- May 25, 2004
- Article
Specialization and Its Discontents: The Pernicious Impact of Regulations Against Specialization and Physician Ownership on the U.S. Healthcare System
Keywords: Health Care and Treatment; Ownership; Governing Rules, Regulations, and Reforms; Health Industry; United States
Herzlinger, Regina E. "Specialization and Its Discontents: The Pernicious Impact of Regulations Against Specialization and Physician Ownership on the U.S. Healthcare System." Circulation 109, no. 20 (May 25, 2004): 2376–2378.
- 2019
- Chapter
Characterizing the Drug Development Pipeline for Precision Medicines
By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement... View Details
Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.
- 01 Sep 2023
- News
Elevator Pitch: Standard of Care
Illustration by Drue Wagner Mike H. M. Teodorescu (DBA 2018) CEO, SurgiBox Dan Brown (DBA 2019) CFO Concept: Founded in the wake of Haiti’s 2010 earthquake, SurgiBox’s lead product is a portable operating room that fits into a backpack and runs on a rechargeable... View Details
- January 2021 (Revised March 2021)
- Case
Serum Institute of India (SII): Racing to Save Lives During a Pandemic
By: Rohit Deshpandé, Anjali Raina and Rachna Chawla
The CEO of Serum Institute of India (SII), a $12.8 billion Indian Family business is faced with a risky choice between principles and profit. SII is the largest manufacturer of vaccines in the world and Adar Poonawalla, the CEO and son of the founder has to decide how... View Details
Keywords: Business Ethics; Healthcare; COVID-19; Vaccines; Family Business; Ethics; Health Care and Treatment; Health Pandemics; Leadership; Corporate Accountability; Fairness; Growth and Development Strategy; Health Industry; India; South Asia
Deshpandé, Rohit, Anjali Raina, and Rachna Chawla. "Serum Institute of India (SII): Racing to Save Lives During a Pandemic." Harvard Business School Case 521-028, January 2021. (Revised March 2021.)
- May 2024
- Case
SofMedica Group: Managing Growth
By: Boris Groysberg and Sarah L. Abbott
SofMedica Group had expanded from its origins as a medical equipment distributor in Romania to a holding company with four business lines operating in six countries. This expansion had been driven by SofMedica’s mission: to make cutting edge medical technology... View Details
Keywords: Growth; Healthcare Access; Healthcare; Medical Devices; Medical Equipment & Devices; Medical Care; Eastern Europe; Quality Management System; Health Care and Treatment; Growth Management; Education; Organizational Change and Adaptation; Quality; Leadership; Mission and Purpose; Expansion; Developing Countries and Economies; Technological Innovation; Health Industry; Medical Devices and Supplies Industry; Europe; Romania
Groysberg, Boris, and Sarah L. Abbott. "SofMedica Group: Managing Growth." Harvard Business School Case 424-027, May 2024.
- Article
Value of New Performance Information in Healthcare: Evidence from Japan
By: Susanna Gallani, Takehisa Kajiwara and Ranjani Krishnan
Mandatory measurement and disclosure of outcome measures are commonly used policy tools in
healthcare. The effectiveness of such disclosures relies on the extent to which the new information produced by the mandatory system is internalized by the healthcare... View Details
Keywords: Value Of Information; Feedback; Patient Satisfaction; Healthcare; Health Care and Treatment; Satisfaction; Information; Measurement and Metrics; Performance Improvement
Gallani, Susanna, Takehisa Kajiwara, and Ranjani Krishnan. "Value of New Performance Information in Healthcare: Evidence from Japan." International Journal of Health Economics and Management 20, no. 4 (December 2020): 319–357.
- Article
Time-Driven Activity-Based Costing in Breast Cancer Care Delivery
By: Navraj S. Nagra, Elena Tsangaris, Jessica Means, Michael J. Hassett, Laura S. Dominici, Jennifer R. Bellon, Justin Broyles, Robert S. Kaplan, Thomas W. Feeley and Andrea L. Pusic
We used time-driven activity-based costing (TDABC) to calculate the complete cost of breast cancer care—initial treatment planning, chemotherapy, radiation therapy, surgical resection and reconstruction, and ancillary services (psychosocial oncology, physical therapy.... View Details
Nagra, Navraj S., Elena Tsangaris, Jessica Means, Michael J. Hassett, Laura S. Dominici, Jennifer R. Bellon, Justin Broyles, Robert S. Kaplan, Thomas W. Feeley, and Andrea L. Pusic. "Time-Driven Activity-Based Costing in Breast Cancer Care Delivery." Annals of Surgical Oncology 29, no. 1 (January 2022): 510–521.
- December 2017
- Article
Is There a Doctor in the House? Expert Product Users, Organizational Roles, and Innovation
By: Riitta Katila, Sruthi Thatchenkery, Michael Christensen and Stefanos A. Zenios
We explore the impact on innovation that professional end-users of a product have as inventors, executives, and board members in a young firm. In contrast to prior literature, which has emphasized technology roles, we put the spotlight on the executive and governance... View Details
Keywords: Innovation; User Innovation; Healthcare; Innovation and Management; Entrepreneurship; Medical Devices and Supplies Industry
Katila, Riitta, Sruthi Thatchenkery, Michael Christensen, and Stefanos A. Zenios. "Is There a Doctor in the House? Expert Product Users, Organizational Roles, and Innovation." Academy of Management Journal 60, no. 6 (December 2017): 2415–2437.
- January–February 2013
- Article
Fairness, Efficiency and Flexibility in Organ Allocation for Kidney Transplantation
By: Dimitris Bertsimas, Vivek F. Farias and Nikolaos Trichakis
We propose a scalable, data-driven method for designing national policies for the allocation of deceased donor kidneys to patients on a waiting list, in a fair and efficient way. We focus on policies that have the same form as the one currently used in the United... View Details
Keywords: Health Care Policy; Healthcare; Fairness; Resource Allocation; Policy; Health Care and Treatment; Medical Specialties; Health Industry; United States
Bertsimas, Dimitris, Vivek F. Farias, and Nikolaos Trichakis. "Fairness, Efficiency and Flexibility in Organ Allocation for Kidney Transplantation." Operations Research 61, no. 1 (January–February 2013): 73–87.
- September 2022
- Article
The Impact of Financial Assistance Programs on Health Care Utilization: Evidence from Kaiser Permanente
By: Alyce S. Adams, Raymond Kluender, Neale Mahoney, Jinglin Wang, Francis Wong and Wesley Yin
Most hospitals have financial assistance programs for low-income patients. We use administrative data from Kaiser Permanente to study the effects of financial assistance on health care utilization. Using a regression discontinuity design based on an income threshold... View Details
Keywords: Healthcare; Utilization; Financial Assistance; Health Care and Treatment; Social Issues; Poverty; Health Industry
Adams, Alyce S., Raymond Kluender, Neale Mahoney, Jinglin Wang, Francis Wong, and Wesley Yin. "The Impact of Financial Assistance Programs on Health Care Utilization: Evidence from Kaiser Permanente." American Economic Review: Insights 4, no. 3 (September 2022): 389–407.
- January 2014 (Revised January 2014)
- Supplement
GlaxoSmithKline in China (C)
By: John Quelch and Margaret L. Rodriguez
Keywords: China; Healthcare; Pharmaceutical Sales; Ethics; Multinational Firms and Management; Pharmaceutical Industry; China
Quelch, John, and Margaret L. Rodriguez. "GlaxoSmithKline in China (C)." Harvard Business School Supplement 514-092, January 2014. (Revised January 2014.) (This case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.)